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Abstract 
Drug-target interaction (DTI) prediction has become a foundational task in 
drug repositioning, polypharmacology, drug discovery, as well as drug 
resistance and side-effect prediction. DTI identification using machine 
learning is gaining popularity in these research areas. Through the years, 
numerous deep learning methods have been proposed for DTI prediction. 
Nevertheless, prediction accuracy and efficiency remain key challenges. 
Pharmaco-electroencephalogram (pharmaco-EEG) is considered valuable in 
the development of central nervous system-active drugs. Quantitative EEG 
analysis demonstrates high reliability in studying the effects of drugs on the 
brain. Earlier preclinical pharmaco-EEG studies showed that different types 
of drugs can be classified according to their mechanism of action on neural 
activity. Here, we propose a convolutional neural network for EEG-mediated 
DTI prediction. This new approach can explain the mechanisms underlying 
complicated drug actions, as it allows the identification of similarities in the 
mechanisms of action and effects of psychotropic drugs. 
Keywords: Deep learning, machine learning, EEG, convolutional neural 
network, classification, drug-target interaction prediction 
 
 
 
 
 
 
 
1 Introduction 
Drug-target interaction (DTI) prediction has become one of the most 
significant techniques in pharmacology-related areas, including 
polypharmacology, drug repositioning, and drug discovery, as well as side-
effect and drug resistance prediction [1]. At present, the ligand-based, target-
based, and chemogenomic methods are recognized as three key 
computational approaches for predicting DTI [2]. 
The ligand-based approach predicts interactions by comparing the 
chemical structure of a new ligand to known ligands. However, ligand-based 
methods are ineffective if there is an insufficient number of known ligands 
[3]. 
For target-based approaches (e.g., docking simulation methods), the target 
protein structures are necessary for simulation, which becomes inapplicable 
when pharmacological targets are unknown or the structures of target proteins 
are too complex to obtain [3,4]. 
A chemogenomic approach has successfully been applied in drug discovery 
and repositioning. This method integrates the chemical space of ligands and 
the genomic space of target proteins into a unified pharmacological space. In 
the case of a chemogenomic approach for psychotropic drugs, the major 
challenge is the scarcity of known ligands, targets, and drug-protein 
interactions [5,6]. 
The specificity of psychotropic drug action is reflected in the bioelectric 
activity of the brain [7]. By binding to targets with complementary structures, 
psychotropic drug molecules modify the electrical behavior of neurons and 
lead to specific electroencephalogram (EEG) reactions [8]. These biological 
reactions correlate with target binding and can be analyzed using 
computational models. This concept is supported by abundant evidence from 
several previous pharmaco-EEG studies. Pharmaco-EEG is very important in 
the development of central nervous system (CNS)-active compounds, as well 
as drug resistance and side-effect prediction [9]. Various validated methods 
are available for exploring the mechanism of action and effects of drugs on 
the brain [10]. The modulation of serotonergic, dopaminergic, noradrenergic, 
cholinergic, or opioidergic neurotransmission causes specific changes in EEG 
frequency [11,12,13]. Different drugs may induce the same EEG pattern, and 
despite the large interindividual variability, many EEG features are 
considered characteristic and unique to specific compounds [8,14,15]. 
Machine learning methods help extract information from EEG recordings, 
and with increasing frequency, are considered perspective neuroscientific 
tools [16,17]. Convolutional neural network (CNN) is currently the dominant 
deep learning strategy for EEG classification [18]. CNNs are widely adopted 
to features of EEG signals to assess the magnitude of pharmacological effects; 
it can specifically be used to predict and monitor the depth of anesthesia 
[19,20,21]. 
DTI prediction methods use both biological and chemical features of ligands 
and targets, and different machine learning techniques can be employed 
[3,5,22].  
Here, we propose a new intracranial EEG (i-EEG)-mediated deep learning 
method that addresses DTI prediction as an i-EEG classification and 
clustering task in multidimensional space (bottleneck feature space between 
the encoder and the decoder), which represents similarities between the 
mechanisms of action of drugs and their effects on the CNS (Figure 1). This 
approach is based on the assumption that drugs with similar effects on EEG 
are likely to interact with similar pharmacological targets and elicit similar 
psychotropic effects. It allows inferring potentially new mechanisms and 
effects of new compounds under study that are mapped close to known drugs 
in the unified parameter space. 
 
 Figure 1. Overall study design. Intracranial electroencephalogram (i-EEG) is 
recorded from the animal after drug administration and fed into the neural 
network. The outputs of the bottleneck layer are clustered and then the 
distances between the clusters are calculated. 
2 Materials and methods 
2.1 Subjects 
The experiments were carried out using inbred male rats weighing 390–500 
g obtained from the Rappolovo Animal Breeding Center (Leningrad Oblast, 
Russian Federation). The animals were kept under a 12/12-h light/dark cycle 
and standard vivarium conditions (air temperature 23 ± 2 °C, continuous air 
supply and exhaust ventilation, and sanitary control) with free access to water 
and food. 
2.2 Electrodes 
The electrodes are made of silver/silver chloride (Ag-AgCl) wire (260 μm, 
RK 50-7-22) (Figure 2A) and are connected to a socket-contact (BL-T; 
resistance less than 0.01 Ω) with an insulated copper cable (MGTF 0.03; 
length 20–30 mm) (Figure 2B). The electrode is coated with two layers of 
heat-shrinkable tubing (polyethylene terephthalate); the first yellow layer 
(Figure 2C) serves as an insulator, whereas the second blue layer (Figure 
2D) restricts electrode insertion. The electrodes were then assembled into an 
8-channel connector (BLD-8, glass-filled nylon) (Figure 2E). Each electrode 
assembly was assigned an identification number. 
 
 
Figure 2. Electrode assembly for intracranial electroencephalogram (i-EEG) 
recordings in rats. (A) electrode; (B) copper cable; (C) insulator; (D) 
restrictor; and (E) connector. 
 
2.3 Electrode implantation 
Implantation was performed under general anesthesia with urethane at a 
dose of 1.5 mg/kg. The animals were stabilized using stereotaxic instruments 
(SR-5R-HT; Narishige Group, Tokyo, Japan) with blunt ear bars. Trepanation 
holes (1 mm diameter) were drilled into the skull at the designated points 
(Table 1, Figure 3) with periodic interruptions to avoid bone overheating. 
 
Table 1. Stereotactic coordinates of electrodes and fixing screws 
Rostrocaudal localization Left Right 
Olfactory bulbs FS (6.60; 2.00) Ground OB (6.60; -2.00) 
Primary motor cortex A1 (0.00; 2, 00) A2 (0.00; -2.00) 
Primary somatosensory cortex P3 (-4.08; 2.00) P4 (-4.08; -2.00) 
Secondary visual cortex O1 (-7.08; 2.00) O2 (-7.08; -2.00) 
Cerebellum FS (0; -11.64) 
FS, fixing screw; OB, olfactory bulbs. 
  
Figure 3. Schematic representation of the electrode placement for intracranial 
electroencephalogram (i-EEG) recording in a rat.  
 
Two stainless-steel fixing anchor screws were mounted into the skull. The 
electrodes were inserted after epidural administration in trepanation holes and 
fixed with self-hardening polymer (Protacryl-M; Stoma, Kharkiv, Ukraine). 
The connector was glued directly to the skull and fixing screws. The 
connector was closed with a plastic cap to protect it from contamination and 
mechanical damage. All rats were then transferred to a temperature-controlled 
recovery environment to reach a normal state before recording commenced. 
2.4 Experimental protocol 
After 7 days of rehabilitation, the animals were randomized and 
administered various anticonvulsants at the maximum single therapeutic dose 
(conversion factor from humans to rats used in this study was 5.9 as 
recommended [23]) or subconvulsive dose for substances with proconvulsant 
activity (Table 2). After reaching the peak concentration (depending on the 
pharmacokinetic properties of the drug) under control of the operator, brain 
activity was recorded for 10 min. 
 
 
 
 
 Table 2. Characteristics of psychotropic drugs used in this study  
Substance Mechanism Effect 
Diazepam (6 mg/kg, po) 
Phenazepam (1 mg/kg, po) 
Chloral hydrate (100 mg/kg, ip) 
GABA-mimetics 
Anticonvulsant Pregabalin (60 mg/kg, po) 
Gabapentin (360 mg/kg, po) 
Calcium channel inhibitors 
Carbamazepine (200 mg/kg, po) 
Eslicarbazepine (160 mg/kg, po) 
Sodium channel inhibitors 
Corazol (pentylenetetrazole; 20 
mg/kg, ip) 
Picrotoxin (2 mg/kg, ip) 
GABA antagonists 
Proconvulsant 
Pilocarpine (60 mg/kg, ip) 
Arecoline (40 mg/kg, ip) 
Cholinomimetics 
GABA, gamma-aminobutyric acid; ip, intraperitoneal injection; po, 
administration per os. 
 
2.5 i-EEG Recording 
A laboratory electroencephalograph (NVX-36; MKS, Moscow, Russian 
Federation) was used to record bioelectrical activity. Intracranial EEG signals 
were recorded at a sampling rate of 500 Hz, in a bipolar montage. Electrode 
impedance was < 5 kΩ. 
i-EEG montage (Table 1): Olfactory bulbs (OB) (ground); P3-A1 (channel 
1); O1-A1 (channel 2); P4-A2 (channel 3); O2-A2 (channel 4). 
All data were uploaded to the cloud and logged in a spreadsheet. The EEG 
signals used in the dataset are available online 
(http://dx.doi.org/10.17632/gmkbhj28jh.1). 
2.6 Dataset structure 
Each subject had some individual characteristics that affected both the 
background EEG signal and changes in the EEG signal associated with drug 
exposure. Therefore, the dataset was compiled in a way to increase the 
diversity of individually associated signal features, which justifies the use of 
inbred animals of different ages and weights. Signals during drug exposure 
were recorded from five different rats for each drug.  
The total size of the dataset for algorithm learning included 16,500 samples. 
Each sample had a duration of 2 s and a sampling rate of 500 Hz. As the EEG 
was recorded simultaneously from four derivations, one signal in the dataset 
contained 4000 data points. Additional filters were not used because they do 
not significantly affect CNN training and result accuracy [18]. 
In 5-fold cross-validation, the whole dataset (including EEG samples from 
all individuals for all drugs) was divided into five equally sized folds using 
four for training and one for prediction. Each fold was used exactly once for 
prediction. Resulting statistical metrics were averaged over all five runs. 
2.7 Hardware and software specifications 
The deep learning system was trained on a workstation equipped with one 
GPU GeForce GTX 660 (Nvidia, Santa Clara, CA). The neural network 
model was built and trained using the Tensorflow Python library. Clustered 
data was visualized using the t-distributed stochastic neighbor embedding (t-
SNE) method [24]. 
 
3 Calculation  
EEG signals cannot be modeled by some known parametric function of 
time; however, they can be approximated with any accuracy by an artificial 
neural network. In addition, neural networks are suitable for solving the 
problem of EEG signal classification with a rich spectrum that has no analytic 
representation [25]. 
Considering the efficiency of the neural network as a classifier and 
parameterizer of complex EEG signals, a unique architecture was proposed 
(Figure 4). The CNN architecture was built taking into account that networks 
for processing quasi-periodic signals do not require much depth [26,27]. 
 
 Figure 4. System architecture combining a classifier and an autoencoder. A 
special method of selective reduction of neurons allows the representation of 
electroencephalogram (EEG) signals in the bottleneck layer as a set of 
parameters. The classifier determines which features are more representative 
of pharmacological properties. Decoder reconstructs the original signal. 
 
Four signals from different EEG channels were used as inputs in the 
network. These signals were converted to 1000 × 4 2D images and passed to 
the convolutional layer. The network was trained using the Adam method 
with a batch size of 100. There were two consecutive convolutional layers in 
the network. The first layer contained ten convolutional filters (neurons) with 
a kernel size of 50 × 4. The second convolutional layer also consisted of ten 
neurons with a kernel size of 20 × 4. 
Let y[n] be an input EEG signal. In the case of a four-channel signal, y[n] 
has the form: y[n] = (y1[n], y2[n], y3[n], y4[n]), where the index at y 
corresponds to the channel number, and n = 0 ... 1000 is the serial number of 
a discrete sampling point in time. 
The signal y[n] was appended with L extra zeros. The new signal t is denoted 
by Y(0)[n] and serves as input to the first convolutional layer. The output of 
the first convolutional layer is as follows: 
          





 


1
1
0
011 ][ReLU r
L
l
rr bnlYlwnz  
where L is the length of the convolutional filters, r = 0, 1, ..., R – 1, (R = 10 is 
the number of convolutional filters), 
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1
 is the impulse response of the 
filters, and 
 1
rb represents bias. 
The input signal in the second convolutional layer is 
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where 
  mw rr
2
 is the impulse response of convolutional filters and 
 2
rb  
represents biases. The second convolutional layer passes the outputs to the 
max-pooling layer, which reduces the size of the 
  mzr
2
 signal 16 times at 
the expense of dropping out the smallest values. The output signal is then 
converted to a one-dimensional array 
  qY 2 . This array is compressed by 
the fully connected encoder layer into a set of parameters x[k]: 
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where 
 code
qw and 
 codeb  are the weights and biases, respectively, of the 
encoder layer. In this case, k = 0 ... K, where K is the number of signal 
parameters. Q is the length of 
  qY 2 . 
Next, the signal x[k] is transmitted to the decoder layer to reconstruct the 
original signal y[n] by minimizing the error: 
Eautoencoder =      ,
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In addition, the signal x[k] is transmitted to the classifier layer to identify 
the drug class. Each EEG signal used in training has its one-hot number.  
The output of the classification layer is denoted as p[c], where c = 0 ... P, 
and P is the number of drugs. 
Classification error during training was defined as the cross-entropy 
between the values p[c] obtained by the network and the real class numbers 
ptrue[c], in which the signal y[n] corresponds to:  
Eclassifier = H(p[c], p
true[c]).  
During training on a set of signals recorded upon exposure to different 
drugs, the neural network clustered the signals in the multidimensional space, 
where the parameters x[k] were coordinates in this space.  
The center of the cluster corresponding to an arbitrary drug A was 
determined as follows: 
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where M is the number of signals for each drug in the dataset. 
The distance between the clusters, i.e., the similarity of two arbitrary drugs 
A and B was determined using the following formula: 
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The closer the clusters were in the parameter space, the more similar the 
EEG signals. 
The network learning cycle consisted of two stages. The autoencoder was 
trained first, i.e., the weights of the convolutional and fully connected layers 
were adjusted, the output of which was a reconstructed signal. At the second 
stage, the classifier was trained, i.e., the weights of convolutional layers and 
a fully connected layer were adjusted, the output of which was the drug 
number (class).  
To determine the minimum number of parameters required to approximate 
and classify the EEG signal, as well as to interpret these parameters, we used 
a new method of selective reduction of neurons in the bottleneck layer. 
The uniqueness of the proposed method relies on the type of dropout used 
during training, in which neurons were not turned off in a random order but 
are disabled from the end. The difference between the classic dropout and 
truncation for an arbitrary fully connected layer is illustrated in Figure 5. 
 
 
Figure 5. Dropout and truncation. Neurons are represented by circles. The 
black circles indicate active neurons while the red denotes neurons that were 
disabled during training. 
 
This training method assumes that neurons in the bottleneck layer were 
selected according to their contribution to the results. Neurons with small n 
values contributed the most, while those with high n values contributes the 
least. By disabling neurons at the end of the layer, it was easy to plot the 
accuracy of signal reconstruction and the accuracy of classification depending 
on the size of the bottleneck, i.e., the number of parameters used to describe 
the EEG after just one full cycle of neural network training. 
 
4 Results 
4.1 Choosing the number of neurons in the bottleneck 
To demonstrate the effectiveness of truncation and provide a rationale for 
the chosen architecture, we carried out several experiments with a simple 
training set consisting of signals for two drugs (arecoline and chloral hydrate). 
We determined the dependence of EEG signal reconstruction accuracy 
(defined as standard deviation) on the number of neurons (n) in the bottleneck 
with truncation and dropout. In both cases, this dependence was obtained by 
dropping out neurons from the end of the bottleneck (Figure 6). Further, we 
showed the relationship between the quality of the network operation and n 
by manually setting the number of neurons in the bottleneck (started with one 
neuron and increased by ten up to 100 neurons) and re-training the network 
for each n (brute force).  
 
 
Figure 6. Dependence of the signal reconstruction accuracy on the number of 
neurons in the bottleneck layer. The curves for truncation and brute force are 
almost the same, while the curve for truncation is built n times faster because 
in this case, the network needs to be trained only once. As can be seen in the 
graphs, the optimal choice is about 50–60 neurons in the bottleneck layer. 
 
4.2 EEG classification 
The classification accuracy was assessed using a 5-fold cross-validation 
method. The average probability of correct classification (for 11 classes) 
based on the cross-validation test was 0.58 ± 0.013 (mean ± standard 
deviation). The obtained classification accuracy significantly exceeded the 
accuracy for a random classifier (random guessing), which was 0.0909 for 11 
drugs (11 classes). 
The learning curves of the described network with truncation trained on the 
dataset that contained EEG signals from 11 drug groups are shown in Figure 
7. 
 
 
 
Figure 7. The learning curves of the neural network. (A) The signal 
reconstruction error (± standard deviation [SD]) of the test dataset during 
А
. 
B
. 
training. (B) Accuracy of the classifier (± SD) of the test dataset during 
training.  
 
Using the described algorithm, we carried out experiments on the 
parameterization of the EEG signal with a layer of a fully connected 
autoencoder bottleneck. Using the neural network, we could represent a signal 
with a duration of up to 2 s as a function with 80 parameters (Figure 8). At 
the same time, the use of more than 20 parameters for classification was 
impractical. 
 
   
А
. 
 
 
Figure 8. Determining the optimal number of parameters used by the network 
to approximate the electroencephalogram (EEG) signal. (A) Dependence of 
autoencoder error (± standard deviation [SD]) on the number of parameters 
in the bottleneck layer. (B) Dependence of classifier accuracy (± SD) on the 
number of parameters. Values were calculated using the test dataset.  
 
Using the network shown in Figure 5 only as a classifier for EEG signals 
recorded under drug exposure, it was possible to obtain a classification 
accuracy of at least 90% in the test set for four drugs with different 
mechanisms of action. The dependence of the classification accuracy of the 
test set signals on the number of drug classes is shown in Figure 9. The test 
set consisted of signals that were not used in the training set. 
 
B
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Figure 9. Dependence of the classification accuracy of drugs in the test 
dataset on the number of classified drugs (± standard deviation [SD]).  
 
4.3 EEG clustering 
The parameters obtained in the bottleneck layer are features of the EEG 
signal, which are descriptive of the pharmacological profile of a substance. 
Sample signals produced many parameter samples that approximately 
coincided, and are thus localized in clusters in the Euclidean space.  
Parameter sets defined for drug classes in a 50-dimensional space (50 
neurons in the bottleneck) were projected into 2D space using the t-SNE 
method [24]. The data structure is shown in Figure 10, where four distinct 
clusters corresponding to four drugs were visualized. The neural network 
architecture without a decoder tended to produce data that were visualized as 
more distinctly isolated clusters. 
 
Figure 10. t-Distributed stochastic neighbor embedding (t-SNE) map of 
intracranial electroencephalogram (i-EEG) signal bottleneck parameters, with 
four highlighted drug classes. Plots generated with the perplexity of 5 and 
3000 iterations. (A) Neural network architecture without a decoder. (B) 
Complete architecture (both a classifier and an autoencoder). dia, diazepam; 
phe, phenazepam; are, arecoline; pil, piloсarpine. 
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t-SNE visualization of a large dataset with 11 drug groups is shown in 
Figure 11. The cluster distribution patterns seemed less interpretable 
intuitively. However, it was observed that gamma-aminobutyric acid 
(GABA) receptor agonists and antagonists are located in opposite orientations 
from each other. 
 
 
Figure 11. t-Distributed stochastic neighbor embedding (t-SNE) map of 
intracranial electroencephalogram (i-EEG) signal bottleneck parameters, with 
11 highlighted drug classes. Plots generated with the perplexity of 5 and 3000 
iterations. Network architecture without the decoder. gab, gabapentin; dia, 
diazepam; car, carbamazepine; pre, pregabalin; esl, eslicarbazepine; phe, 
phenazepam; are, arecoline; cor, corazol; pic, picrotoxin; pil, piloсarpine; chl, 
chloral hydrate. 
 
Decreasing the dimension from 50 to 2 led to the loss of information. At the 
same time, the similarity of drugs could be defined as the distance between 
the clusters using the Euclidean distance (Figure 12).  
The results confirmed that for a dataset with 11 drug classes, it was possible 
to correctly determine the qualitative distribution of the drug to the 
pharmacological group using the proposed clustering algorithm.  
 
 
Figure 12. The relative proximity of clusters in the multidimensional 
parameter space as an indicator of the similarity of pharmacological 
properties of substances. The y-axis represents the coefficients of similarity 
of the drug effects on the electroencephalogram (EEG) signal. These 
coefficients are dimensionless, relative, and calculated as distances between 
clusters in unified multidimensional parameter space. The adjacent clusters 
were formed by drugs having a common pharmacological mechanism of 
action. dia, diazepam; phe, phenazepam; chl, chloral hydrate; car, 
carbamazepine; esl, eslicarbazepine; pre, pregabalin; gab, gabapentin; pil, 
piloсarpine; are, arecoline; cor, corazol; pic, picrotoxin. 
 
Pregabalin was the most similar to gabapentin. Both drugs bind to an 
additional subunit (α2δ) of voltage-gated calcium channels in the CNS, which 
are reportedly involved in epileptogenesis [28]. Eslicarbazepine and 
carbamazepine had an anticonvulsant effect, which was associated with 
inhibition of potential-dependent sodium channels in neurons of the brain. 
EEG signals obtained after the administration of GABA-A receptor 
benzodiazepine site agonists (diazepam and phenazepam) were distributed 
close to a cluster of signals recorded upon chloral hydrate exposure, which is 
metabolized to the active component of trichloroethanol and implements its 
effects through the regulation of GABA-receptor complex [29]. Clusters of 
GABA-A agonists were at a maximum distance from GABA-A receptor 
antagonists, picrotoxin and corazole (pentylenetetrazole), as well as 
cholinomimetics, pilocarpine, and arecoline. 
In general, the EEG signals obtained after the administration of drugs with 
an anticonvulsant effect had greater relative proximity to each other than 
those after the administration of drugs with a pro-convulsive effect. 
 
5 Discussion 
The neural network algorithm proposed here effectively recognized patterns 
of the neuronal response upon administration of various psychotropic drugs 
and could cluster substances based on the mechanism of action and 
similarities of their therapeutic effects.  
i-EEG-mediated DTI prediction has an advantage in cases where classical 
DTI prediction approaches are ineffective; for example, in cases of multiple 
sclerosis, Parkinson’s disease, and Alzheimer’s disease, as well as other 
neurodegenerative and psychiatric diseases. This is because (a) an insufficient 
number of ligands are synthesized or not synthesized at all or (b) adequate 
targets are not identified. 
In the present study, even in the absence of ligands with the same 
mechanism of action in the dataset, the algorithm could predict the possible 
effects of a substance, which opens up vast opportunities for the research and 
development of new anticonvulsants or other substances with psychotropic 
activity. In addition, there is a high potential for using this approach for 
repositioning drugs that are already used in clinical practice. 
The doses of psychotropic substances were selected to exclude the 
development of severe impairment of consciousness and coordination of 
movements or convulsive phenomena that would lead to pronounced and 
easily recognizable signal changes. This allowed us to conclude that the 
proposed neural network has relatively high sensitivity and specificity, even 
under moderate pharmacological influence on brain function. 
The productivity of this approach may be increased by replacing the animal 
subject with a nerve cell culture or living brain slice [30]. In future studies, 
the registration of neuronal activity may be carried out using in vitro 
microelectrode arrays (MEAs), such as planar MEAs and 3D HD-MEAs. The 
characteristics of the pharmacological response are not diminished or changed 
by the nature of dissociated neuronal networks when compared to in vivo 
models, i.e., MEAs can be used to study pharmacological effects on neural 
activity in a more controlled and straightforward environment [31].  
The use of the decoder made it possible to extract features from the 
bottleneck that were needed not only for classification but also for obtaining 
the signal properties associated with the characteristics of research subjects 
and measuring equipment. If we used a decoder and the signals were still 
clustered (Figure 10), then we could say that the activation of neurons in the 
bottleneck reflected the slowly changing parameters of the EEG signal. 
Having determined the number of parameters describing the signal, we can 
estimate in subsequent studies the optimal requirements for a dataset, such as 
its combinatorial dimension, the number of individuals per drug, and the size 
of the signal sample for one drug. In addition, this approach made it possible 
to describe the EEG signal with a small number of parameters, which means 
that if we were to develop a methodology for interpreting these parameters, 
there would be new possibilities for EEG analysis. 
 
6 Conclusion 
We proposed an original approach for i-EEG-mediated DTI prediction 
using CNNs with a modified algorithm for selective reduction of neurons in 
the bottleneck layer. The suggested method associates a compound and a 
target or a compound and an effect through an intermediate link in the form 
of a bioelectric response to a substance. 
The essence of this new approach lies in the fact that the nervous tissue is 
a perfect biological detector of psychotropic substances, as psychotropic 
action is directly reflected in bioelectric activity. The neural network 
algorithm efficiently recognizes patterns of neuronal response and can 
identify a substance via both the mechanism of action and therapeutic effect. 
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